
Please try another search
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India.
Name | Age | Since | Title |
---|---|---|---|
Navrattan Munjal | 72 | 1986 | Non-Executive Director |
Vikrant Rai Mehta | 66 | 1993 | Joint MD & Whole Time Director |
Sanjeev Rai Mehta | 68 | 2006 | Executive Chairman |
Rishav Mehta | 33 | 2010 | Non-Executive Director |
Gopal Munjal | 66 | 1986 | CEO, MD & Whole Time Director |
Bhupinder Singh | 60 | 2022 | Non-Executive Independent Director |
Jagvir Singh Ahluwalia | 75 | 2017 | Non-Executive Independent Director |
Subhash Chander Galhotra | 78 | 2016 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review